BioCentury | Apr 20, 2015
Company News

iDD Biotech, Genmab deal

...million) in development and sales milestones, plus single-digit royalties. iDD did not respond to inquiries. iDD Biotech S.A.S....
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

...has a program targeting celiac disease. On May 14, it received exclusive, worldwide rights from iDD Biotech...
...in 2016 for both diseases. Companies and Institutions Mentioned Calypso Biotech S.A. , Geneva, Switzerland iDD Biotech...
...status: Preclinical Founded: 2013 by Yolande Chvatchko and Alain Vicari University collaborators: None Corporate partners: iDD Biotech...
BioCentury | May 20, 2013
Company News

Calypso Biotech, iDD Biotech deal

...development to treat Crohn's disease (see BioCentury, March 11). Calypso Biotech S.A. , Plan-les-Ouates, Switzerland iDD Biotech...
Items per page:
1 - 3 of 3
BioCentury | Apr 20, 2015
Company News

iDD Biotech, Genmab deal

...million) in development and sales milestones, plus single-digit royalties. iDD did not respond to inquiries. iDD Biotech S.A.S....
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

...has a program targeting celiac disease. On May 14, it received exclusive, worldwide rights from iDD Biotech...
...in 2016 for both diseases. Companies and Institutions Mentioned Calypso Biotech S.A. , Geneva, Switzerland iDD Biotech...
...status: Preclinical Founded: 2013 by Yolande Chvatchko and Alain Vicari University collaborators: None Corporate partners: iDD Biotech...
BioCentury | May 20, 2013
Company News

Calypso Biotech, iDD Biotech deal

...development to treat Crohn's disease (see BioCentury, March 11). Calypso Biotech S.A. , Plan-les-Ouates, Switzerland iDD Biotech...
Items per page:
1 - 3 of 3